Investments, Funding & Disinvestment

AdipoLABs operates as a Ministry of Health (MOH)-registered medical device establishment under the Medical Device Authority (MDA), providing regulatory credibility and demonstrating commitment to quality and innovation.

The total USD20.9 million funding will be divided into two tranches, with the release of the second contingent on outcomes from the ongoing ‘SEALS’ phase 2 clinical trial.

The international event brings together leading experts and practitioners from around the world to share knowledge, advance modern surgical techniques, and shape the future of robotic surgery.

This new facility aims to help Liberia achieve WHO Maturity Level 3, a benchmark the country has sought for decades without success.

The approved funding will help countries build systems that keep communities safe, particularly in cross-border areas where health risks are highest.

The acquisition centers on Alcyone’s innovative ThecaFlex DRx drug delivery system, an experimental implantable device that represents a significant advancement in treating neurological disorders.

Construction at the MTC is currently underway and is scheduled for completion during the first half of 2027.

The pharmaceutical giant will pay USD221.50 per share in cash to purchase the US biotech company, which has developed an innovative platform called drug-Fc conjugates (DFCs).

The acquisition aims to connect ambulatory care centers, teleradiology services, and hospital systems through unified imaging technology.

This new facility will replace the existing laboratory, which Minister of Agriculture and Animal Resources Mark Cyubahiro Bagabe noted has served for nearly four decades and no longer meets current needs.